1-chloroethyldimethyl-carbamate | 92600-24-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-chloroethyldimethyl-carbamate
• 英文别名: alpha-monochloroethyl N,N-dimethylcarbamate；1-chloroethyl N,N-dimethylcarbamate
• CAS: 92600-24-3
• 化学式: C₅H₁₀ClNO₂
• 分子量: 151.593
• InChiKey: YGGHIXQTSIQHAX-UHFFFAOYSA-N

物化性质

• 沸点：
  161.4±19.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-chloroethyldimethyl-carbamate 在 potassium carbonate 、 caesium carbonate 作用下， 以 乙腈 为溶剂， 反应 20.5h， 生成 1-((5-ethyl-6-fluoro-4-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(2,2,2-trifluoroethoxy)pyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-yl)oxy)ethyl dimethylcarbamate
  参考文献：
  名称：

  PRODRUGS OF PAN-KRAS INHIBITORS

  摘要：

  The present invention relates to prodrugs of specific compounds that inhibits multiple mutated forms of KRas, i.e., the pan-KRas inhibitors. In particular, the present invention relates to prodrugs of these pan-KRas compound, pharmaceutical compositions comprising the prodrugs and methods of use therefor.

  公开号：

  WO2023244600A1
• 作为产物：
  描述：

  1-氯乙基氯甲酸酯 在 二甲胺 作用下， 生成 1-chloroethyldimethyl-carbamate
  参考文献：
  名称：

  O,S-dialkyl S-[carbamyloxyalkyl] dithiophosphates and their use as

  摘要：

  通式（I）的O，S-二烷基S- [氨基甲酰氧基烷基] 二硫代磷酸酯，其中独立的R.sup.1和R.sup.2各自是不超过4个碳原子的烷基，而R.sup.3，R.sup.4和R.sup.5则是氢或不超过6个碳原子的烷基，或者R.sup.4和R.sup.5与它们所结合的氮原子一起形成饱和或烯丙基不饱和的环，该环中含有不超过6个碳原子，可能包含一个或多个氧，硫或氮原子，用于控制昆虫或螨类。

  公开号：

  US04599329A1

文献信息

• [EN] PRODRUGS OF KALLIKREIN INHIBITORS<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE LA KALLICRÉINE
  申请人：BIOCRYST PHARM INC

  公开号：WO2018081513A1

  公开（公告）日：2018-05-03

  Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity. (I) (II) (III)

  公开了式I、II和III的化合物及其药学上可接受的盐，它们是激肽释放酶抑制剂。还提供了包含此类化合物的药物组合物，以及使用这些化合物和组合物治疗和预防获得性或遗传性血管性水肿或其他以异常激肽释放酶活性为特征的疾病和病症的方法。(I) (II) (III)
• [EN] NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS D'HYDROXYESTER, LEUR PROCÉDÉ DE PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2016207225A1

  公开（公告）日：2016-12-29

  Compounds of formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R13, Ra, Rb, A and n are as defined in the description. Medicaments containing them for use in the treatment of cancers.

  式（1）中R1、R2、R3、R4、R5、R6、R7、R13、Ra、Rb、A和n的化合物如描述中所定义。包含它们的药物用于治疗癌症。
• ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US20150210666A1

  公开（公告）日：2015-07-30

  An object of the present invention is to provide a compound that is useful as an orally available anti-HCV agent. The present invention relates to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. This compound has an anti-HCV activity and is useful as a medicine.

  本发明的目的是提供一种可口服的抗丙型肝炎病毒药物化合物。本发明涉及一种由式（1）所表示的化合物或其药学上可接受的盐。该化合物具有抗丙型肝炎病毒的活性，是一种有用的药物。
• ORALLY ADMINISTRABLE VIRIDIOFUNGIN DERIVATIVE HAVING ANTI-HCV ACTIVITY
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP2886530A1

  公开（公告）日：2015-06-24

  An object of the present invention is to provide a compound that is useful as an orally available anti-HCV agent. The present invention relates to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. This compound has an anti-HCV activity and is useful as a medicine.

  本发明的目的是提供一种可用作口服抗 HCV 药物的化合物。本发明涉及一种由式（1）表示的化合物或其药学上可接受的盐。该化合物具有抗 HCV 活性，可用作药物。
• Prodrugs of kallikrein inhibitors
  申请人：BioCryst Pharmaceuticals, Inc.

  公开号：US10759759B2

  公开（公告）日：2020-09-01

  Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity.

  所公开的是式 I、II 和 III 的化合物及其药学上可接受的盐，它们是卡利克瑞林的抑制剂。此外，还提供了包含此类化合物的药物组合物，以及涉及使用这些化合物和组合物治疗和预防获得性或遗传性血管性水肿，或其他以异常卡利克瑞林活性为特征的疾病和病症的方法。